Fig. 3

CD34 immune-expression in the cerebral cortex by IHC: [a] Group 1 (non-infected group); [b] Group 2 (infected non-treated group); [c] Group 3 (albendazole-treated group); [d] Group 4 (curcumin-treated group); [e] Group 5 (dual curcumin and albendazole therapy group). Strong positive CD34 protein expression can be observed in the brain endothelium and inflammatory cells of the infected group. Mild to moderate expression is observed in the curcumin-treated group, while moderate protein expression can be noticed in the albendazole-treated group. Very few inflammatory cells weakly expressing CD34 expression can be observed in the dual curcumin and albendazole therapy group; scale bar 50 μm. [f] Count of CD34 immune-reactive cells in the different study groups; a: Significant versus negative control, b: Significant versus positive control, c: Significant versus curcumin 150 group at P < 0.05 using Tukey Kramer post-Hoc comparison test. at P < 0.05 using Tukey Kramer post-Hoc comparison test